Fresenius : Resolutions of the Annual General Meeting of Fresenius SE & Co. KGaA

At today's Annual General Meeting in Frankfurt am Main, the shareholders of Fresenius SE & Co. KGaA approved the proposals of the General Partner and the Supervisory Board by a large majority.

Wolfgang Kirsch, Chairman of the Supervisory Board, thanked the Management Board and emphasized Fresenius' strong performance in extremely challenging geopolitical times. "Against this backdrop, Fresenius has performed well as a leading healthcare company compared to the competition and has improved significantly in operational terms." He added that the #FutureFresenius program is strengthening Fresenius sustainably in the interests of all stakeholders. "The new Management Board team under the leadership of Michael Sen brings experience and complementary skills, team spirit and abilities, which will allow us to achieve the ambitious corporate goals and successfully implement #FutureFresenius," said Kirsch.

CEO Michael Sen thanked the shareholders for supporting the #FutureFresenius journey, as well as the members of the Supervisory Board and Chairman Wolfgang Kirsch for their excellent cooperation. "We have successfully completed the first phases of #FutureFresenius and regained trust. We shall now tackle the remaining phases with motivation and optimism," he stressed.

A large majority of 99.84% of shareholders voted in favor of approving the annual financial statements. The shareholders approved the Compensation Report for the 2023 fiscal year by 93.06%. Large majorities of 96.48% and 95.90% respectively approved the actions of the Management Board and the Supervisory Board in 2023.

At the Annual General Meeting of Fresenius SE & Co. KGaA, 72.65% of the registered capital was represented.

Attachments

• Original Link
• Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 17 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 May 2024 13:17:03 UTC.